Publications
212
Citations
976
Est. group size
~56
Recurring co-author estimate
Active years
28
Publishing since 1999
Mingjia Li's work focuses on advanced non-small cell lung cancer (NSCLC), particularly how tumor genetics (like PD-L1 expression and KRAS gene mutations) affect patient response to immunotherapy and targeted drugs such as pembrolizumab and KRAS G12C inhibitors. Recent projects also explore using AI models (transformers) to analyze complex, long-term patient outcome data. This research is aimed at improving treatment selection and predicting outcomes for lung cancer patients.
Publication output grew sharply from near zero in 2017-2018 to a peak of 87 in 2023, followed by a decline in 2024-2025, suggesting a period of intense productivity that has since slowed somewhat.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Journal for ImmunoTherapy of Cancer · 2025
- Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Journal for ImmunoTherapy of Cancer · 2025
- Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
Lung Cancer · 2025
- Terrestrial water storage changes of Qinghai Lake on the Tibetan Plateau from joint inversion of GNSS and InSAR data
2025
- Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Table S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025
- Journal of Clinical Oncology×25
- Regular and Young Investigator Award Abstracts×9
- Cancer Immunology Immunotherapy×8
- Journal of the National Comprehensive Cancer Network×8
- Cancer Medicine×4
- Yusuf Açıkgöz
Medicine · The Ohio State University
- Ha Tran
Medicine · The Ohio State University
- Bert H. O’Neil
Medicine · Indiana University
- Wei Chen
Medicine · The Ohio State University
- Greg Andrew Durm
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile